What is LYRA's health score?

Lyra Therapeutics, Inc. (LYRA) has a TradeApes health score of 34 out of 100, rated Weak. This composite score evaluates financial strength, operating trends, valuation, capital allocation, and risk factors.

What is LYRA's estimated fair value?

Based on our 5-year discounted cash flow model, Lyra Therapeutics, Inc.'s estimated fair value is $12.57 per share, representing a 1708.8% upside from the current price. This is a model estimate, not a price target or investment recommendation.

Is LYRA undervalued or overvalued?

Our model currently rates LYRA as Undervalued. This assessment combines health metrics, valuation multiples, and market sentiment. Individual investors should conduct their own due diligence.

Crunching the numbers for LYRA... Refresh in a moment for the full analysis.

Lyra Therapeutics, Inc. (LYRA)

Healthcare Undervalued low weak

$0.69

Updated: 2026-06-05

TradeApes Score

Financial Strength

45 Mixed

Operating Trend

30 Weak

Relative Value

40 Weak

Capital Allocation

10 Stressed

Risk

35 Weak

Est. Fair Value $12.57

DCF Upside +1708.8%

Sector Rank #3290 of 6719

Key Findings

+ Low leverage — net debt/EBITDA below 1×

Unlock Full Report →

− Sharp revenue decline — sales down more than 15% year over year

Unlock Full Report →

4 free score cards remaining

TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor. The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.

11 sector-leading stocks delivered to your inbox every Sunday. Free.

No spam. Unsubscribe anytime.